Na’an T320: The Breakthrough Battle of Shanxi’s Biomedical Industry

The rise of Na’an cannot be separated from the “Shanxi complex” of its founder, Dr. Qu Zhican. In 2018, Qu Zhican gave up the favorable conditions overseas and led her team to return home to start a business. Through the Bio-Lattix core technology platform, she broke through the bottleneck of ADC drug development and achieved precise treatment design targeting tissue factor (TF). Pre clinical data show that T320 has a tumor inhibition rate of more than 90% in animal models of pancreatic cancer, and a variety of solid tumor indications have been arranged.

山西传统产业资本对生物医药的青睐成为纳安发展的重要推力。2023年，纳安完成1.2亿元A轮融资，并登陆山西股权交易中心“晋兴板”，为后续上市铺路。这种“煤企转型投资科创”的模式正在重塑山西产业格局，政府也从“管理者”转向“服务者”，构建起“政-产-研”协同生态。

The favor of Shanxi’s traditional industrial capital towards biomedicine has become an important driving force for the development of Na’an. In 2023, Na’an completed a 120 million yuan Series A financing and landed on the Shanxi Equity Trading Center's “Jinxing Board”, paving the way for subsequent listing. This model of “coal enterprises transforming and investing in science and technology innovation” is reshaping the industrial landscape of Shanxi, and the government is shifting from “managers” to “service providers”, building a collaborative ecosystem of “government-industry-research”.

纳安T320的突破证明内陆省份可通过差异化创新实现“换道超车”，为山西从“黑色经济”转向“绿色产业”提供了新动能。

The breakthrough of the Na’an T320 proves that inland provinces can achieve “lane changing overtaking” through differentiated innovation, providing new impetus for Shanxi to shift from a “coal economy” to a “green industry”.

（图源网络 侵删）

(The image source from the internet. If infringement, it will be deleted.)

来源：中华网综合整理

Source: Comprehensive collation by sx.china.com